Abstracts

HIV ANTIBODY GLYCOFORMS MODULATE IMMUNE COMPLEX-DRIVEN INNATE AND ADAPTIVE IMMUNITY

HIV broadly neutralizing antibodies (bNAbs) confer protection following passive immunization, but the immunological mechanisms that drive their development in a fraction of HIV infected individuals are poorly understood. Structural features of bNAbs indicate that they originate from extensive B cell germinal center reactions, which rely on immune complex (IC)-mediated delivery of antigen to follicular dendritic…

EFFECT OF SWITCHING TO RALTEGRAVIR AND/OR ADDING LOSARTAN ON HIV IMMUNE ACTIVATION

Inflammation and immune activation markers associated with end-organ diseases like atherosclerosis are higher in treatment-suppressed HIV patients than in non-HIV population. No therapies have been developed to effectively target these mediators. A decrease of immune activation markers after raltegravir intensification and anti-inflammatory properties of the angiotensin receptor antagonist losartan have been reported. The objective of…

A BISPECIFIC APPROACH FOR TARGETING NEGATIVE CHECKPOINT RECEPTORS IN HIV-1 LATENCY

HIV infection is associated with persistent upregulation of PD-1, LAG-3, TIGIT and perhaps other checkpoint molecules, particularly on HIV-specific T cells. We hypothesize that simultaneous engagement of multiple targets via bispecific antibodies (BsAbs) will enhance anti-HIV efficacy compared to single or combination approaches. Two BsAbs targeting the negative checkpoint receptors PD-1 & LAG-3 and PD-1…

HIV INFECTION OF TARGET CELLS IN PEDIATRIC TONSIL IS INHIBITED BY AN HSP90 INHIBITOR

HIV-1 transmission via breastfeeding, accounting for ~half of the 150,000 pediatric infections annually, often goes unrecognized for many months leading to high viral loads. Therefore, immediate cART cannot be expected to achieve rapid viral suppression in these infants, potentiating the need for an additional antiviral strategy. HIV utilizes cellular heat shock protein 90 (Hsp90) for…

EBV BORF2 INHIBITS AND SEQUESTERS HUMAN APOBEC3B TO PROTECT VIRAL GENOME INTEGRITY

Human cells express up to seven different DNA cytosine deaminases, APOBEC3(A3)A-H, which have overlapping functions in innate antiviral immunity. Several A3s, most notably A3G, have been well characterized in inhibiting HIV-1 replication by converting C-to-U in retroviral single-stranded cDNA replication intermediates, thereby generating hypermutated viral genomes. To overcome A3-mediated restriction, viruses have evolved counteraction measures…